Oliver Lagore Vanvalin Investment Group Has $226,000 Holdings in Eli Lilly and Company (NYSE:LLY)

Oliver Lagore Vanvalin Investment Group lifted its position in shares of Eli Lilly and Company (NYSE:LLY) by 27.7% in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 387 shares of the company’s stock after buying an additional 84 shares during the quarter. Oliver Lagore Vanvalin Investment Group’s holdings in Eli Lilly and Company were worth $226,000 at the end of the most recent reporting period.

Several other large investors also recently modified their holdings of LLY. Lipe & Dalton bought a new position in Eli Lilly and Company during the fourth quarter worth $26,000. Thompson Investment Management Inc. bought a new position in Eli Lilly and Company during the third quarter worth $27,000. Retirement Group LLC boosted its stake in Eli Lilly and Company by 159.1% during the second quarter. Retirement Group LLC now owns 57 shares of the company’s stock worth $27,000 after acquiring an additional 35 shares in the last quarter. Legacy Financial Group LLC bought a new position in shares of Eli Lilly and Company in the third quarter valued at $35,000. Finally, Optiver Holding B.V. bought a new position in shares of Eli Lilly and Company in the third quarter valued at $36,000. 82.53% of the stock is currently owned by institutional investors and hedge funds.

Eli Lilly and Company Trading Down 0.6 %

Shares of LLY opened at $745.95 on Friday. The firm has a market cap of $708.77 billion, a price-to-earnings ratio of 128.61, a PEG ratio of 1.64 and a beta of 0.34. The company has a debt-to-equity ratio of 1.69, a quick ratio of 0.73 and a current ratio of 0.94. Eli Lilly and Company has a fifty-two week low of $367.35 and a fifty-two week high of $800.78. The firm has a 50 day moving average price of $764.24 and a 200-day moving average price of $658.28.

Eli Lilly and Company (NYSE:LLY) last issued its earnings results on Tuesday, February 6th. The company reported $2.49 EPS for the quarter, topping the consensus estimate of $2.30 by $0.19. Eli Lilly and Company had a net margin of 15.36% and a return on equity of 51.22%. The company had revenue of $9.35 billion for the quarter, compared to the consensus estimate of $8.95 billion. During the same period in the previous year, the firm earned $2.09 earnings per share. The firm’s revenue for the quarter was up 28.1% on a year-over-year basis. As a group, equities research analysts forecast that Eli Lilly and Company will post 12.52 earnings per share for the current year.

Wall Street Analyst Weigh In

A number of research firms have weighed in on LLY. Citigroup raised their price objective on shares of Eli Lilly and Company from $675.00 to $895.00 and gave the company a “buy” rating in a research note on Tuesday, April 2nd. BMO Capital Markets raised their price target on shares of Eli Lilly and Company from $710.00 to $865.00 and gave the company an “outperform” rating in a research report on Wednesday, February 7th. Barclays raised their price target on shares of Eli Lilly and Company from $680.00 to $810.00 and gave the company an “overweight” rating in a research report on Wednesday, February 7th. The Goldman Sachs Group raised their price target on shares of Eli Lilly and Company from $650.00 to $723.00 and gave the company a “neutral” rating in a research report on Thursday, April 11th. Finally, Cantor Fitzgerald restated an “overweight” rating and set a $815.00 price objective on shares of Eli Lilly and Company in a report on Monday. Three equities research analysts have rated the stock with a hold rating and seventeen have assigned a buy rating to the stock. According to MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $728.05.

Insider Buying and Selling

In related news, major shareholder Lilly Endowment Inc sold 54,032 shares of Eli Lilly and Company stock in a transaction on Monday, January 29th. The shares were sold at an average price of $645.07, for a total value of $34,854,422.24. Following the transaction, the insider now directly owns 99,488,598 shares of the company’s stock, valued at $64,177,109,911.86. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. 0.13% of the stock is owned by insiders.

Eli Lilly and Company Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.